NRIX is trading 4.3% up today at $23.88 as investors continue to react to a newly announced global collaboration with Roche for the BTK degrader bexobrutideg.
- The agreement includes a broad co-development and co-commercialization plan spanning hematology, immunology, and neurology.
- The partnership significantly improves perceptions of Nurix’s funding runway and long-term commercial potential.
- Positive momentum is further supported by a broader rally across U.S. equity markets.